Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
|
|
- Evangeline Cox
- 6 years ago
- Views:
Transcription
1 Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
2 The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics are about gathering medical data to be transformed into actionable information. Condition Data Information Action Sample Test Result Evaluation Treatment Desicion Transforming clinical samples into informed therapeutic action is key in the healthcare value chain. IVD testing has long been a silent champion of healthcare, influencing over 60 % of clinical decision-making, while accounting for only about 2 % of total healthcare spending. IVD accounts for ~2 % of worldwide healthcare spending 1,2 IVD influences >60 % of clinical decision-making 1,2 IVDs provide excellent healthcare value. 1 European Diagnostic Manufacturers Association (EDMA), 2009; based on: The Lewin Group, commissioned by Advamed, The Value of Diagnostics, The Lewin Group, The Value of Diagnostics Innovation, Adoption, and Diffusion in Healthcare (2005).
3 Roche Diagnostics are an integral part in the healthcare value chain Healthy Asymptomatic/Symptomatic disease Chronic disease Diagnostics Prevention Screening Diagnosis Prognosis Stratification Treatment Monitoring Pharmaceuticals Today, IVDs are an integral part of decision-making along the entire continuum of a patient s health or disease, enabling physicians to make full use of IVDs along the healthcare value chain.
4 Roche Leadership in Diagnostics 3 Roche Diagnostics areas of expertise Roche Diagnostics covers all IVD segments in all major healthcare areas. Performed on blood, tissue or other patient samples IVDs are a critical source of objective information for improved disease management and patient care. Roche Diagnostics offers the industry s broadest range of diagnostic tests. Our pioneering technologies and solutions not only help ensure an accurate diagnosis, they can detect the risk of disease, predict how a disease may progress, and enable the right treatment decision at the outset. We help patients gain control over chronic conditions by enabling both physicians and patients to monitor treatment progress. And, through our successful collaboration with laboratories, we provide the fast and reliable results needed for lifechanging decisions. Roche Diagnostics serves customers spanning the entire healthcare spectrum from research institutions, hospitals, and commercial laboratories to physicians and patients. Main Focus Areas Cardiology Infectiology Oncology Women s Health CNS
5 7,000 Installed systems 29,000 Installed systems 1,500 Installed systems 7,000 Installed systems 18,000 Installed systems Roche Diagnostics commitment Providing innovation and excellence today and tomorrow Roche offers a pioneering partnership to make the maximum contribution to patient care. As a leader in IVD solutions, 3 we are your dedicated partner supporting you through our immunoassay technologies for centralised and decentralised settings, in molecular and tissue testing, as well as automation and IT solutions. In a pioneering partnership, we provide products that increase testing efficiency and deliver medical value, whilst supporting you every step of the way with our global and local expertise; dedicated service and support teams are available in over 130 countries. Our commitment and rich pipeline of differentiated solutions and technologies will facilitate your provision of improved patient care today and also tomorrow. 20 years of innovation and experience with Elecsys For two decades now, Roche has been continuously investing in the development of Elecsys assays, delivering fast and reliable testing solutions for laboratories all over the world. ElectroChemiLuminescence (ECL) technology is Roche s highly innovative detection technology for heterogeneous immunoassays. Since the launch of the first Elecsys 2010 analyser for small to mid-range laboratories in 1996, the extraordinary success story of the Elecsys platform and ECL technology has continued to set the standard in immunochemistry. More than 35,000 instruments* testify to the outstanding success of Elecsys systems, assays and the ECL technology. Every second, 60 results are reported in laboratories all over the world, amounting to more than 1.9 billion tests in Roche Diagnostics professional IVD analysers combine innovative technologies with accurate, precise and reliable patient results that contribute to better patient care. 3 Source: Roche Annual Report January * Status 2016
6 Personalised Healthcare (PHC) What is PHC all about? PHC is about providing the right treatment for the right group of patients. Roche s strengths in pharmaceuticals and diagnostics along with advances in science and technology have made fitting treatments to patients possible. Did you know that previously, only half of all patients, on average, actually benefited from their treatment? Today, up to 80 % of patients respond to their targeted therapies. Before PHC After PHC From better disease understanding to supporting regulatory approvals.
7 Ferring Pharmaceuticals and Roche collaborate to develop personalised infertility treatment As a leader in personalised healthcare we are expanding this approach to ever more areas of unmet medical need such as infertility and women s health. In collaboration with Ferring, we are excited to play a pioneering role in individualising fertility management while continuing to invest in medically differentiated tests. Jean-Claude Gottraux, Head of Centralised and Point of Care Solutions
8
9 Excellence for your Biomarker-driven Strategies The integral process to support drug development with CDx At Roche we combine technical competence with therapeutic insight. Development of a successful targeted therapy involves both diagnostic and pharmaceutical (clinical) concurrent co-development of the drug and the IVD CDx test. From a regulatory standpoint, the identification of the biomarker and development of the IVD CDx test require extensive testing, validation and approval in parallel with the clinical development of the therapeutic product. The Food and Drug Administration (FDA) states that, ideally, a therapeutic product and its corresponding IVD CDx device should be developed contemporaneously, with the clinical performance and clinical significance of the IVD CDx device established using data from the clinical development program of the c orresponding therapeutic product. 4 Roche provides the strong partnership required for development of the therapy and the CDx test, ensuring a smooth and organized development process, in order to achieve timely regulatory marketing authorisations. FDA definition of CDx 4 An IVD CDx device is an IVD device that provides information that is essential for the safe and effective use of a corresponding therapeutic product. The use of an IVD CDx device with a therapeutic product is stipulated in the instructions for use in the labelling of both the diagnostic device and the corresponding therapeutic product, including the labelling of any generic equivalents of the therapeutic product. Roche the partner of choice for PHC Solutions Knowledge is leading to a dramatic increase in the identification of biological targets to fight many diseases. In collaboration with large and small pharmaceutical companies, we identify and develop innovative CDx to target those patients who are likely to respond to specific therapies. Because we recognize the tremendous potential for these solutions, we continue to focus on addressing unmet medical needs by developing the cutting-edge tools you need. In-house Skills Know-how PHC Tools Structure Roche offers all the necessary components to meet complex challenges that make PHC a reality. 4 Food and Drug Administration. August 6, Accessed Aug 2016.
10 Delivering the promise of biomarker-driven strategies Partnership throughout the drug development process In the early stages of discovery, biomarkers can provide insights on the causes or pathophysiology of the disease biology and the mode of action of a therapeutic molecule. During these early phases of a project, the biomarker and diagnostics teams work together with the ultimate goal of developing a reliable biomarker-based test the CDx test, which will help predict which patients will respond to targeted therapies. This is central to the concept of PHC. A multitude of potential biomarkers have been identified that can be used to evaluate disease processes, understand disease diversity, identify drug targets and recognize differences between individual patients. Once a biomarker is found, a standardized diagnostic test can be developed and prepared for regulatory approval alongside a drug. Using biomarkers early can avoid exposing study participants to excessive doses of the drug compound in development and related potential side effects. The future of sustainable healthcare depends on diagnostics. Pharmaceuticals Research and early development Clinical development Commercialisation Target section Lead generation Phase 0 Phase I Phase II Phase III Filing Market Phase IV Discovery phase Exploratory phase Proof of concept Confirmatory phase Biomarker development Target identification Companion diagnostic feasibility and utility Patient selection Dx launch/post-launch assessment Tailored prescribing and monitoring Diagnostics Roche provides the strong partnership required to achieve timely regulatory approvals for therapeutic products and their CDx tests.
11 We bring over 200 biomarker projects with over 55 pharma partners with strong track records reliably on time and on budget We reduce biotech companies development and commercialization risks We offer a differentiated, broad instrument and reagent portfolio Ventana Medical Systems
12 For more information please contact Published by Roche Diagnostics International Ltd Forrenstrasse Rotkreuz, Switzerland 2016 All trademarks mentioned enjoy legal protection.
Personalized Healthcare Diagnostik und Therapie aus einer Hand
Personalized Healthcare Diagnostik und Therapie aus einer Hand Priv.-Doz. Dr. med. Christian Meisel DVFA Life Science Conference, 17 June 2009 1 The Challenge Personalised healthcare Roche s unique position
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationRecent Trends in Companion Diagnostic Test Development Partnerships
Recent Trends in Companion Diagnostic Test Development Partnerships Andrew S. Thompson, PhD, Director of Therapy and Analysis, GlobalData Medical, London Tyler Fletcher, Global Head, GlobalData Medical,
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationWelcome to our 29 th Global GS1 Healthcare Conference. Follow us on Twitter and tweet about the #GS1HCuae
Welcome to our 29 th Global GS1 Healthcare Conference Follow us on Twitter and tweet about the conference! @GS1Healthcare #GS1HCuae GS1 2016 Dr. Ina Trapp Roche Diagnostics Implementation of GS1 barcode
More informationAccelerating the Adoption of Companion Diagnostics
Accelerating the Adoption of Companion Diagnostics Our mission: to improve the lives of all patients afflicted with cancer Our vision: to empower our customers by providing the highest quality, most innovative
More informationStart With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development. Paul Docherty PhD Relationship Management
Start With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development Paul Docherty PhD Relationship Management Disclaimer This presentation contains my personal views and research
More informationUniquely positioned for the future
Uniquely positioned for the future Severin Schwan, CEO Roche Group Bellevue meets Management Seminar, January 09 1 This presentation contains certain forward-looking statements. These forward-looking statements
More informationUniquely positioned for the future. Severin Schwan, CEO Roche Group Merrill Lynch, London, 16 September 2008
Uniquely positioned for the future Severin Schwan, CEO Roche Group Merrill Lynch, London, 16 September 2008 1 This presentation contains certain forward-looking statements. These forward-looking statements
More informationRoche in Switzerland
Roche in Switzerland A leader around the world and at home Last year Roche employed some 13,000 employees from over 90 countries in Switzerland. This makes Switzerland one of Roche s three largest locations
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationRoche: adapting to the changing environment. Severin Schwan, CEO Roche Group London, 15 September 2010
Roche: adapting to the changing environment Severin Schwan, CEO Roche Group London, 15 September 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationMedical breakthroughs have always driven our business
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationThe NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England
The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.
More informationAnnual General Meeting Roche Holding Ltd 6 March 2012
r Annual General Meeting Roche Holding Ltd 6 March 2012 Address by Franz B. Humer Chairman of the Board of Directors (Check against delivery.) Address by Franz B. Humer Page 2/12 Dear Shareholders, Ladies
More informationPersonalized healthcare Getting from promise to reality
Personalized healthcare Getting from promise to reality Severin Schwan, CEO Roche Group Swiss-American Chamber of Commerce, 26 August 2009 1 Roche The challenge Personalised healhcare Implementation at
More informationMedia Release. Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology
Media Release Basel, 12 January 2015 Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology Collaboration leverages both companies strengths
More informationLead the way. Molecular Imaging. GE Healthcare. imagination at work
2010 General Electric Company All rights reserved. General Electric Company reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time
More informationSpecialty Lab Services. Deep science at scale
Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical
More informationGUIDE HEA
Companies are often overwhelmed by the field of digital health. From digital and med device companies to biotechnology and pharmaceutical companies, there is a struggle to cut through the noise of numerous
More informationBringing a successful partnership to the next level
Bringing a successful partnership to the next level Basle, 21 July 2008 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as
More informationCancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development
Cancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development Phil L Huillier Director Cancer Research Technology Ltd London, UK Who we are Cancer Research
More informationAnnual General Meeting Roche Holding Ltd 13 March 2018
Annual General Meeting Roche Holding Ltd 13 March 2018 Address by Christoph Franz Chairman of the Board of Directors (Check against delivery) Address by Christoph Franz page 2/12 Dear Shareholders, Ladies
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationGlobal IVD Market
Global IVD Market ----------------------------------------------------- 2014 Executive Summary An in-vitro diagnostic test is performed outside of a human body in an artificial environment (e.g. laboratory).
More informationNew Tools for the Enhanced
New Tools for the Enhanced Management of Chronic Disease Based on a Proprietary, Point of Care, Electrochemical Detection System Universal Biosensors Investor Presentation February 2010 1 Important disclaimer
More informationAnnual General Meeting Roche Holding Ltd 4 March 2014
r Annual General Meeting Roche Holding Ltd 4 March 2014 Address by Severin Schwan Chief Executive Officer (Check against delivery.) Address by Severin Schwan page 2/11 Shareholders, Ladies and Gentlemen,
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationGlobal In-Vitro Diagnostics (IVD) Market Report
Global In-Vitro Diagnostics (IVD) Market Report ----------------------------------------- 215 Executive Summary The diagnostic industry is widely classified into two types: In-vitro diagnostics and In-vivo
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationOverview: The future of medicine is personalised. Severin Schwan, CEO
Overview: The future of medicine is personalised Severin Schwan, CEO This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationRoche Healthcare Consulting Lead the way
Consulting Services Powered by Roche Diagnostics Each day your challenges intensify Value comes when you think beyond With budget cuts and shrinking margins, you re constantly facing new obstacles to overcome,
More informationMargins of pharmaceutical companies are continuing to decline the future lies in new ecosystems
Karin Mateu Media Relations Tel.: +41 (0) 58 286 44 09 karin.mateu@ch.ey.com Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems Glaxo is leading the way in
More informationAT A GLANCE. inventivhealthclinical.com
AT A GLANCE inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 PHASE I-IIA 03 PHASE IIB-III 04 LATE STAGE 05 STRATEGIC RESOURCING 06 BIOANALYTICAL 07 QUALITY ASSURANCE 08 CONSULTING 09 THERAPEUTIC
More informationMaking the case for Personalised Medicine
Making the case for Personalised Medicine The biopharmaceutical industry perspective Barbara Freischem Executive Director European Biopharmaceutical Enterprises Who we are EBE represents the voice of biopharmaceutical
More informationIn Vitro Companion Diagnostic Devices
4 th of Joint Conference of Taiwan and Japan on Medical products regulation In Vitro Companion Diagnostic Devices 2016/12/7 Aoyagi Yumiko Ministry of Health, Labour and Welfare Medical Device Evaluation
More informationWebinar July 9, Noon. The Essentials of Diagnostics: Introduction to Molecular Diagnostics
Webinar July 9, 2013 12 Noon The Essentials of Diagnostics: Introduction to Molecular Diagnostics 1 DxInsights mission is to educate healthcare stakeholders on the power and value of diagnostics and their
More informationAlmac Overview.
Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationMolecular Diagnostics: Market Segmentation and Opportunities
Molecular Diagnostics: Market Segmentation and Opportunities October 2010 This market report is published by DeciBio, LLC. All rights reserved. Reproduction or redistribution of this report in any form
More informationChallenges in developing Biomarker Assays for patient selection and Companion Diagnostic (CDx) Assays in early and late stage of drug development
Challenges in developing Biomarker Assays for patient selection and Companion Diagnostic (CDx) Assays in early and late stage of drug development The 9 th JBF Symposium February 8 th, 2018 Kenji Nakamaru
More informationIntroduction to Drug Development
Introduction to Drug Development Yves Geysels, PhD Head Clinical Research Operations, Belgium Past President of the Associoation of Clinical Research Professionals (ACRP) Board Member of the European Forum
More informationAnnual General Meeting Roche Holding Ltd 14 March 2017
Annual General Meeting Roche Holding Ltd 14 March 2017 Address by Christoph Franz Chairman of the Board of Directors (Check against delivery) Address Christoph Franz Page 2/10 Dear Shareholders, Ladies
More informationPartnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC
Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC To Our Potential Partners We offer partners the depth of
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More informationTerminology for personalized medicine
Terminology for personalized medicine Sarah Ali-Khan 1 PhD, Stephanie Kowal 2, Westerly Luth 2, Richard Gold 1 SJD, and Tania Bubela 2 PhD JD 1. Centre for Intellectual Property Policy (CIPP), Faculty
More informationVALUE OF COMPANION DIAGNOSTICS IN PERSONALISED MEDICINE
VALUE OF COMPANION DIAGNOSTICS IN PERSONALISED MEDICINE Stimulating innovation for improving health through companion diagnostics 5 March 2015 I. Introduction Personalised healthcare provides targeted
More informationUBS Global Life Sciences Conference
September 21, 2010 UBS Global Life Sciences Conference Tecan Group AG Thomas Bachmann, CEO September 21, 2010 / p2 / UBS Global Life Sciences Conference Introducing Tecan Provider of instruments and workflow-solutions
More informationENABLE INJECTIONS AND FLEX SET AMBITIOUS PLANS FOR LARGE VOLUME DRUG DELIVERY
ENABLE INJECTIONS AND FLEX SET AMBITIOUS PLANS FOR LARGE VOLUME DRUG DELIVERY The delivery of high volumes of biologics outside of the clinical setting remains a key challenge in the industry. Here, John
More informationComments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics
Comments from the FDA Working Group on SUBGROUP ANALYSES Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics 1 Outline An intro to FDA EMA and FDA on subgroups Companion
More informationPersonalized Medicine A new challenge for applied human pharmacology?
Personalized Medicine A new challenge for applied human pharmacology? Jochen Theis, MD FFPM InHeCon Leipzig 2 nd March 2012 Personalized Medicine: Predicting Variability in Drug Response InHeCon Jochen
More informationHELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY
HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH
More informationDiagnostics in Oncology Mark Kockx MD, PhD
HistoGeneX The Real World A Specialized of companion Biomarker & Integrated Pathology Laboratory Diagnostics in Oncology Mark Kockx MD, PhD 1 2 HistoGeneX located in Antwerp, Belgium and Chicago, Illinois
More informationGlobal leader in predictive diagnostics ASX: PIQ
Corporate Review Sydney Canary Capital 6 th June 2017 Global leader in predictive diagnostics ASX: PIQ 1 Business model Three synergistic business areas Unifying Promarker platform technology - leverage
More informationTHERAPEUTIC AREAS CARDIOVASCULAR RESEARCH
THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH PPD S CARDIOVASCULAR TEAM: OPTIMIZING TRIALS AND IMPROVING OUTCOMES APPLYING EXPERIENCE, INNOVATION AND EFFICIENCY IN THE FIGHT AGAINST CARDIOVASCULAR DISEASE
More informationChallenges of Biomarker Development. (in Europe)
Challenges of Biomarker Development (in Europe) 1 Disclaimer I work for industry (diagnostics) We have worked with over 30 biopharma companies in the arena of biomarkers The presentation is my own and
More informationHealthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation
Healthcare Healthcare The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation (CPI)
More informationCompanion diagnostics and the IVD Directive 98/79/EC + revision
Companion diagnostics and the IVD Directive 98/79/EC + revision European Perspectives in Personalised Medicine Square-Brussels Meeting Centre Brussels, Belgium 12-13 May 2011 Dr. Anne Van Nerom Rue Juliette
More informationKPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
More informationTo Partner or Not to Partner:
To Partner or Not to Partner: Determining Your Commercialization Plan Written by: Debbi Amanti Belanger, Principal, ClearView Healthcare Partners Deciding whether to partner an important late-stage asset
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationThe importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016
The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016 Marianne Kock, Head of Global Regulatory Affairs & Managing Director, Ferring Pharmaceuticals
More informationThe Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic
The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic 1 The Irish Biomarker Network -Inaugural Workshop Improved Translation of Biomarkers to the Clinic Overview
More information34 th Annual J.P. Morgan Healthcare Conference
34 th Annual J.P. Morgan Healthcare Conference Vincent A. Forlenza Chairman, Chief Executive Officer and President January 13, 2016 Forward-Looking Statements These materials include forward-looking statements
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationCCTG initiative. patient reported outcomes (including wearables)
Executive Summary Canada can be a global leader in the next generation of pharmaceutical and cancer care innovation. The Canadian Cancer Trials Group (CCTG) is requesting $39 million in federal funding
More informationWeek 1: Discovery Biology Basic knowledge and tools used in Research and Development
Downing - Keio Summer School 2018 Healthcare and Biotechnology Course Outline page 1 Strand A: Healthcare and Biotechnology Course Outline This course aims to provide an overview of the current challenges
More informationGlobal In-Vitro Diagnostic Market Report
Global In-Vitro Diagnostic Market Report ----------------------------------------------------- 2013 Executive Summary The process of performing a diagnostic test outside of a living organism in an artificial
More informationRoche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis
Investor Update Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis Data presentations will
More informationSALDA In Vitro Diagnostics in South Africa. Welcome. December 2015
SALDA In Vitro Diagnostics in South Africa Welcome December 2015 Is the IVD industry ready for regulations? What is our collective mandate? We have been asked to ensure the safety and effectiveness of
More informationCan High Performance Computing Help Cure Pharma R&D?
Can High Performance Computing Help Cure Pharma R&D? Philippe Guillet, MD Unité Vieillissement Sanofi R&D Teratec Forum 2013 26/06/13 TERATEC Forum 2013 Ecole Polytechnique Palaiseau June 25-26 2013 Trends
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationIMMUNOASSAY MARKET. Global Forecast to MarketsandMarkets
IMMUNOASSAY MARKET [Technology (Enzyme, Fluorescent, Chemiluminescence, Radioimmunoassay), Analyzers & Reagents, Application (Infectious Diseases, Cancer, Endocrinology, Cardiology), End-Users (Hospitals,
More informationAssociation for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology
Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:
More informationAnnual General Meeting Roche Holding Ltd
r Annual General Meeting Roche Holding Ltd 5 March 2019 Address by Christoph Franz Chairman of the Board of Directors (Check against delivery) Address by Christoph Franz page 2/12 Shareholders, ladies
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More informationCoristo Customer Info Day PSM Product Structure Management. Beat Meier / Martin Behnke Roche Mirko Quintern Coristo
Coristo Customer Info Day PSM Product Structure Management Beat Meier / Martin Behnke Roche Mirko Quintern Coristo Agenda Roche basic facts - History - Solution Overview - Strategic roadmap Project Overview
More informationPharmaPerspectiveonCDx. DrGillian Ellison
PharmaPerspectiveonCDx DrGillian Ellison Pharma Perspective Need for CDx Partnering with Dx company Co- development Launch readiness & LCM Need for CDx Drug development Drug development is a challenging
More informationBiomarkers as an emerging growth area in Denmark
Biomarkers as an emerging growth area in Denmark International Conference on Perspectives in Precision Medicine, Copenhagen March 1, 2018 Kim Holmstrøm, PhD. Chairman of The Danish Biomarker Network R&D
More informationTrend in diagnostic biochip. Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital Handling of the early stage is important for
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationa pioneering & a a vibrant science & technology company
WE ARE WE ARE a pioneering & a a vibrant science & technology company We are Merck a leading science and technology company working in healthcare, life science and performance materials. From the screen
More information2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award
2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award 2018 2018 NORTH AMERICAN REAL-WORLD EVIDENCE ENTERPRISE SOLUTIONS MARKET LEADERSHIP AWARD Contents Background and Company
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationVentana Companion Diagnostics. Building the future of pathology through partnership
Ventana Companion Diagnostics Building the future of pathology through partnership Mission & Vision Overview Companion Diagnostics & the Value of Personalized Healthcare Current State & the Future of Companion
More informationEBE White Paper on Personalised Medicine
EBE White Paper on Personalised Medicine EBE is a specialised group of European Federation of Pharmaceutical Industries and Associations, EFPIA Content p3 p4 p6 p6 p7 p9 p10 p11 p13 p14 Executive Summary
More informationThe Finnish Medicines Agency Fimea is in charge of regulating and developing the pharmaceutical sector to promote the health of Finland s population.
1 (11) FIMEA S STRATEGY 2011 2020 Mission The Finnish Medicines Agency Fimea is in charge of regulating and developing the pharmaceutical sector to promote the health of Finland s population. Fimea s tasks
More informationBIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationa pioneering & a a vibrant science & technology company
WE ARE WE ARE a pioneering & a a vibrant science & technology company We are Merck a leading science and technology company working in healthcare, life science and performance materials. From the screen
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 UBS Australian Healthcare Conference November 2011 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationDevelop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers:
MEDICON VALLEY / 2011 03 Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers: > A pool of highly qualified life-science university graduates and
More informationUBS 2007 Global Life Sciences Conference. September 24, 2007
UBS 2007 Global Life Sciences Conference September 24, 2007 Safe Harbor This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationSustaining long-term growth by focusing on our customers
Strategy in action Sustaining long-term growth by focusing on our customers Our capabilities and customer focused strategy are opening growth opportunities in addressable markets of approximately $8 billion.
More informationInvestor Update. Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
Investor Update Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting Ten medicines featured in over 70 abstracts, including
More information